Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin Conditioning for Allo-HSCT in Aggressive NHL
NCT00644371Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Nov 2007
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), sponsored by GELTAMO. Started Nov 2007; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00644371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00644371.